[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"updates-archive-2026-05-19-1":3},{"date":4,"filings":5,"has_more":593,"limit":594,"page":595,"total_count":596},"2026-05-19",[6,14,21,28,36,43,50,57,63,70,77,82,89,95,101,107,112,117,123,128,133,138,145,150,157,162,167,172,179,186,191,198,203,208,213,219,224,231,236,241,246,251,258,263,268,274,279,284,289,294,299,306,313,319,326,333,338,343,349,354,359,366,372,379,384,390,395,400,407,412,419,424,431,437,442,449,456,463,469,476,483,489,494,499,504,509,514,521,526,531,537,544,549,554,559,564,571,576,581,588],{"company_name":7,"filing_date":8,"filing_source":9,"headline":10,"id":11,"stock_code":12,"summary_text":13},"KDDL Limited","2026-05-19T23:56:40.111000","NSE","KDDL's FY26: Revenue Soars 30%, But Consolidated Profit Dips 5%","6a0caba70c6b4fb98a9297ea","KDDL","*   Consolidated revenue for FY26 grew strongly by 30.3% to ₹2,207.8 Cr, while standalone revenue rose 31.9% to ₹506.0 Cr.\n*   **Key Concern:** Despite strong revenue growth, consolidated net profit (PAT) declined by 5.0% to ₹135.2 Cr, signaling significant margin pressure at the group level, likely within subsidiaries.\n*   The standalone manufacturing business performed well, with its net profit growing 55.6% to ₹76.6 Cr.\n*   Management provided a positive long-term outlook, projecting 20-25% CAGR for its Bracelets and Precision Engineering (EIGEN) segments.\n*   An exceptional expense of ₹2.45 Cr was recorded on the consolidated P&L due to the \"Statutory impact of Labor Codes.\"",{"company_name":15,"filing_date":16,"filing_source":9,"headline":17,"id":18,"stock_code":19,"summary_text":20},"Valiant Laboratories Limited","2026-05-19T23:56:40.040000","Promoter Group Announces Major Shareholding Restructure","6a0cab8ea157653c663a7b3b","VALIANTLAB","*   Valiant Organics Limited, a promoter entity, proposes to acquire a **34.26% stake** in the company from another promoter, Dhanvallabh Ventures LLP.\n*   The transaction is an off-market, inter-se transfer as part of a \"restructuring exercise.\"\n*   Post-transaction, Valiant Organics will become the single largest shareholder, holding 34.26% of the company.\n*   The overall promoter group shareholding percentage will remain unchanged, and the transaction is exempt from a mandatory open offer.",{"company_name":22,"filing_date":23,"filing_source":9,"headline":24,"id":25,"stock_code":26,"summary_text":27},"BLS International Services Limited","2026-05-19T23:56:40.034000","Approves Grant of 150,000 Employee Stock Options","6a0cab81890e096a6fc5f9d2","BLS","*   The Nomination and Remuneration Committee has approved the grant of **1,50,000 Employee Stock Options (ESOPs)** to eligible employees under the \"BLS International Employees Stock Option Scheme-2023\".\n*   The exercise price for these options is fixed at **Rs. 254.70 per option**.\n*   The options will vest equally over a **3-year period**, serving as a long-term incentive and retention tool.\n*   Full exercise of these options could lead to the issuance of **1,50,000 new equity shares**, causing potential dilution for existing shareholders.",{"company_name":29,"filing_date":30,"filing_source":31,"headline":32,"id":33,"stock_code":34,"summary_text":35},"Welspun Living Ltd","2026-05-19T23:51:41.421000","BSE","Pays ₹2.22 Lakh Fine to BSE Under Protest","6a0caa75ec7f5de862c5c4ce","WELSPUNLIV","*   BSE Limited imposed a fine on the company for non-compliance with SEBI regulations regarding the composition of its Stakeholders Relationship Committee (SRC).\n*   The company has paid the fine of ₹2,22,000 (excluding GST) \"in abeyance,\" meaning the payment is made pending a final decision.\n*   Welspun has filed a review application with BSE, requesting a waiver of the fine, and is awaiting the outcome.\n*   The company stated the non-compliance was due to a board change and believes the fine has no material impact on its financials or operations.",{"company_name":37,"filing_date":38,"filing_source":31,"headline":39,"id":40,"stock_code":41,"summary_text":42},"KSE Ltd","2026-05-19T23:51:41.300000","KSE Ltd Proposes Dividend Despite Alarming Q4 Loss","6a0caa8558d87443453a6517","519421","*   The Board proposed a final dividend of \u003Cb>₹7.50 per share\u003C\u002Fb> for FY26.\n*   The company reported a significant net loss of \u003Cb>₹373.42 Lakhs for Q4 FY26\u003C\u002Fb>, a sharp reversal from a ₹3,479.15 Lakhs profit in Q4 FY25.\n*   Full-year Profit After Tax fell 7.96% to ₹8,404.03 Lakhs, as profit from the core \u003Cb>Animal Feed division dropped by 37%\u003C\u002Fb>.\n*   Losses in the \u003Cb>Dairy division widened by 176%\u003C\u002Fb> year-over-year, indicating severe operational challenges.\n*   A \u003Cb>₹5 crore provision\u003C\u002Fb> was made for the upcoming 'New Labour Codes', flagging a potential future liability.\n*   During the year, the company's shares were subdivided from a face value of ₹10 to ₹1.",{"company_name":44,"filing_date":45,"filing_source":31,"headline":46,"id":47,"stock_code":48,"summary_text":49},"Tuticorin Alkali Chemicals And Fertilizers Ltd","2026-05-19T23:51:41.273000","Posts Mixed FY26 Results: Revenue Rises, But Net Profit Plummets 41%","6a0caa70bf8f716f130005d1","506808","*   \u003Cb>Significant Profitability Decline:\u003C\u002Fb> Full-year Net Profit After Tax (PAT) for FY26 dropped by 41.13% to ₹3,661.09 Lakhs from ₹6,218.78 Lakhs in FY25.\n*   \u003Cb>Revenue Growth:\u003C\u002Fb> Despite the profit drop, Total Income from Operations for FY26 grew by 8.67% year-over-year to ₹34,308.57 Lakhs.\n*   \u003Cb>Sequential Weakness:\u003C\u002Fb> The company reported a weak Q4, with revenue declining 16.11% and net profit falling 12.32% compared to the previous quarter (Q3 FY26).\n*   \u003Cb>Profit Anomaly Context:\u003C\u002Fb> The sharp YoY profit decline is magnified because FY25 results included a significant one-time exceptional gain of ₹2,287.81 Lakhs.\n*   \u003Cb>EPS Decreases:\u003C\u002Fb> Basic & Diluted EPS for the year fell to ₹3.00 from ₹3.23 in FY25.",{"company_name":51,"filing_date":52,"filing_source":31,"headline":53,"id":54,"stock_code":55,"summary_text":56},"KDDL Ltd","2026-05-19T23:51:41.239000","FY26 Revenue Soars 31%, But Profits Dip on Margin Pressure","6a0caa8eecaa861d949281fb","KEC","• \u003Cb>Strong Revenue Growth:\u003C\u002Fb> Consolidated revenue for FY26 grew 30.7% YoY to ₹2,153.4 Crores, driven by strong performance in manufacturing and luxury retail (Ethos).\n• \u003Cb>Profitability Decline:\u003C\u002Fb> Despite strong sales, consolidated Profit After Tax (PAT) fell by 5.0% to ₹135.2 Crores, and consolidated EPS dropped to ₹71.63 from ₹76.26.\n• \u003Cb>Margin Squeeze:\u003C\u002Fb> The profit decline was caused by a contraction in EBITDA margin (from 18.1% to 16.4%) and a one-time exceptional expense of ₹2.45 Crores.\n• \u003Cb>Standalone Strength:\u003C\u002Fb> In contrast, the standalone business (excluding subsidiaries like Ethos) performed very well, with its PAT increasing by 55.6%.\n• \u003Cb>Strategic Outlook:\u003C\u002Fb> The company is focused on scaling its new bracelet manufacturing facility and executing the global relaunch of its acquired Swiss watch brand, 'Favre Leuba'.",{"company_name":58,"filing_date":59,"filing_source":31,"headline":60,"id":61,"stock_code":19,"summary_text":62},"Valiant Laboratories Ltd","2026-05-19T23:51:41.162000","Valiant Organics to Acquire 34.26% Stake in Promoter Restructuring","6a0caa64c9cbead9b3c5e347","*   **What's happening:** Valiant Organics Ltd (Acquirer) proposes to acquire a **34.26%** stake in Valiant Laboratories from Dhanvallabh Ventures LLP (Seller) in an off-market deal.\n*   **Impact:** Post-acquisition, Valiant Organics will become the single largest shareholder. The seller's stake will reduce from 46.84% to 12.58%.\n*   **Reason:** The filing states the acquisition is part of a \"restructuring exercise\" undertaken by the acquirer.\n*   **Key Detail:** This is an inter-se transfer within the promoter group, and an exemption from making a mandatory open offer to the public is being claimed.",{"company_name":64,"filing_date":65,"filing_source":9,"headline":66,"id":67,"stock_code":68,"summary_text":69},"Axis Bank Limited","2026-05-19T23:51:39.786000","ESOP Allotment Increases Share Capital","6a0caa4ea157653c663a7b32","AXISBANK","*   Axis Bank has allotted **2,57,834** new equity shares to employees under its Employee Stock Option Plan (ESOP) on May 19, 2026.\n*   This action increased the bank's issued and paid-up share capital by **₹ 5,15,668**.\n*   The total number of equity shares now stands at **3,10,96,04,914**.\n*   The issuance results in a minor equity dilution of approximately **0.0083%**, which is considered immaterial.",{"company_name":71,"filing_date":72,"filing_source":9,"headline":73,"id":74,"stock_code":75,"summary_text":76},"Dishman Carbogen Amcis Limited","2026-05-19T23:51:39.739000","Statutory Auditor Re-appointed for Five-Year Term","6a0caa6fabd16353d20019e0","DCAL","*   The Board of Directors has approved the re-appointment of M\u002Fs. T R Chadha & Co LLP as the company's Statutory Auditors.\n*   The re-appointment is for a term of five consecutive years (60 months), effective from May 19, 2026.\n*   This decision is subject to the approval of shareholders at the upcoming Annual General Meeting (AGM).",{"company_name":71,"filing_date":78,"filing_source":9,"headline":79,"id":80,"stock_code":75,"summary_text":81},"2026-05-19T23:51:39.707000","Board Proposes Re-appointment of Statutory Auditor","6a0caa560c6b4fb98a9297de","*   The Board of Directors has recommended the re-appointment of M\u002Fs. T R CHADHA & CO LLP as the company's Statutory Auditor.\n*   This proposal is subject to the approval of shareholders at the upcoming Annual General Meeting (AGM).\n*   No other material information regarding financials, operations, or corporate actions was disclosed in this filing.",{"company_name":83,"filing_date":84,"filing_source":9,"headline":85,"id":86,"stock_code":87,"summary_text":88},"Healthcare Global Enterprises Limited","2026-05-19T23:51:39.705000","Divests Non-Core Subsidiary BACC for ₹37.64 Crores","6a0caa61890e096a6fc5f9c8","HCG","*   \u003Cb>Action:\u003C\u002Fb> HCG is selling its entire stake in its subsidiary, BACC Health Care Private Limited, for a total consideration of \u003Cb>₹37.64 Crores\u003C\u002Fb>.\n*   \u003Cb>Rationale:\u003C\u002Fb> The sale is a strategic move to exit the non-core fertility and reproductive healthcare business and focus on its primary operations.\n*   \u003Cb>Key Governance Point:\u003C\u002Fb> This is a \u003Cb>Related Party Transaction\u003C\u002Fb>. The buyer, Inviga Healthcare Fund I, is controlled by HCG's Promoter and Chairman, Dr. B.S. Ajaikumar. The company states the deal is at an arm's length basis.\n*   \u003Cb>Deal Structure:\u003C\u002Fb> The payment includes ₹28.23 Crores upfront and a deferred payment of ₹9.41 Crores over 18 months. The transaction is expected to close in 4-5 weeks.",{"company_name":90,"filing_date":91,"filing_source":31,"headline":92,"id":93,"stock_code":75,"summary_text":94},"Dishman Carbogen Amcis Ltd","2026-05-19T23:46:40.845000","Profit Soars 2900%, But Debt Covenants Breached","6a0ca95e58d87443453a6512","*   \u003Cb>Consolidated Net Profit Surges:\u003C\u002Fb> FY26 consolidated Net Profit jumped by 2908% to ₹97.45 Cr, up from ₹3.24 Cr in the previous year.\n*   \u003Cb>Standalone Performance Worsens:\u003C\u002Fb> In stark contrast, the standalone entity's Net Loss widened to ₹(38.40) Cr, with revenue from operations declining by 42%.\n*   \u003Cb>Debt Covenant Breach (Red Flag):\u003C\u002Fb> The company breached financial covenants on its standalone debt as of March 31, 2026. While waivers were obtained, auditors highlighted this as an \"Emphasis of Matter\".\n*   \u003Cb>Major Promoter Loan Proposed:\u003C\u002Fb> The Board approved taking a large loan of up to CHF 200 million (approx. ₹2,452 Cr) from a promoter group company to refinance existing debt, subject to shareholder approval.\n*   \u003Cb>Aggressive Accounting Change:\u003C\u002Fb> The company changed the useful life of its Goodwill to 99 years, which boosted reported Profit Before Tax by ₹6.60 Cr. This was also flagged by the auditors.",{"company_name":96,"filing_date":97,"filing_source":31,"headline":98,"id":99,"stock_code":87,"summary_text":100},"HealthCare Global Enterprises Ltd","2026-05-19T23:46:40.794000","Sells Non-Core Fertility Business for ₹37.64 Cr to Chairman's Fund","6a0ca93decaa861d949281f5","*   HCG is selling its entire stake in its non-core fertility business, BACC Health Care Private Limited, for a total of ₹37.64 crores.\n*   The divestment is part of a strategy to sharpen the company's focus on its core business activities.\n*   **Red Flag:** The buyer is a fund controlled by HCG's own Promoter and Chairman, making this a significant related-party transaction.\n*   The company states the deal is at \"arm's length,\" supported by an independent valuation and a competitive sale process.",{"company_name":102,"filing_date":103,"filing_source":9,"headline":104,"id":105,"stock_code":34,"summary_text":106},"Welspun Living Limited","2026-05-19T23:46:39.953000","Pays BSE Fine Under Protest for Governance Lapse","6a0ca92eabd16353d20019d8","*   Paid a fine of ₹2,22,000 (plus GST) imposed by BSE Limited for non-compliance with SEBI regulations.\n*   The violation concerned the composition of the company's Stakeholders Relationship Committee.\n*   The fine was paid \"in abeyance\" as the company has filed a review application with the BSE, which is currently pending.\n*   Management states the event has no material impact on the company's financials or operations.",{"company_name":64,"filing_date":108,"filing_source":9,"headline":109,"id":110,"stock_code":68,"summary_text":111},"2026-05-19T23:46:39.944000","Axis Bank Allots 257,834 New Shares to Employees","6a0ca924890e096a6fc5f9b5","*   **Action**: Allotment of **257,834** new equity shares under the Employee Stock Option Plan (ESOP).\n*   **Allotment Date**: May 19, 2026.\n*   **New Total Shares**: The company's total number of equity shares has increased to **3,109,604,914**.\n*   **Shareholder Impact**: This action results in a minor equity dilution of approximately **0.0083%**.",{"company_name":64,"filing_date":113,"filing_source":9,"headline":114,"id":115,"stock_code":68,"summary_text":116},"2026-05-19T23:46:39.917000","New Shares Issued Under Employee Compensation Scheme","6a0ca92e0c6b4fb98a9297d8","*   Allotted 257,834 new equity shares following the exercise of employee stock options (ESOP\u002FRSU).\n*   The total paid-up share capital has increased to Rs. 6,219,209,828.\n*   This action results in a minor equity dilution of approximately 0.0083% for existing shareholders.",{"company_name":118,"filing_date":119,"filing_source":31,"headline":120,"id":121,"stock_code":26,"summary_text":122},"BLS International Services Ltd","2026-05-19T23:41:41.717000","FY26 Results: Record Revenue & Visa Profits, But Digital Growth Squeezes Margins","6a0ca820bf8f716f130005c6","*   **Record Performance:** FY26 revenue grew 36.7% YoY to ₹2,998 Cr and EBITDA rose 30.1% YoY to ₹819 Cr, marking the company's highest-ever performance.\n*   **Visa Business Strength:** The core Visa & Consular segment delivered strong profitability, with its EBITDA margin expanding significantly by 560 bps to 40.1%.\n*   **Digital Business Growth:** The Digital segment's revenue surged 114.4% YoY, driven by the consolidation of Aadifidelis Solutions.\n*   **Red Flag - Margin Pressure:** Despite high growth, the consolidated EBITDA margin declined by 140 bps to 27.3%. This was caused by the lower-margin Digital Business, whose own margin contracted from 11.0% to 7.0%.\n*   **Shareholder Payout:** A final dividend of ₹0.5\u002Fshare was recommended, bringing the total FY26 dividend to ₹2.5\u002Fshare (a total payout of ~₹103 Crores).\n*   **Strategic Initiatives:** Partnered with Sypha AI to modernize visa processing and launched an AI Voice Bot for applicants.",{"company_name":90,"filing_date":124,"filing_source":31,"headline":125,"id":126,"stock_code":75,"summary_text":127},"2026-05-19T23:41:41.508000","Consolidated Profits Skyrocket, But Standalone Losses & Key Red Flags Emerge","6a0ca82e58d87443453a650d","*   \u003Cb>Massive Profit Growth (Consolidated):\u003C\u002Fb> Net Profit surged by 2908% to ₹97.45 Cr for FY26, driven by controlled expenses.\n*   \u003Cb>Standalone Weakness:\u003C\u002Fb> In sharp contrast, the standalone entity's Net Loss widened by 289% to ₹38.40 Cr, indicating heavy reliance on subsidiaries.\n*   \u003Cb>Debt Covenant Breach:\u003C\u002Fb> The company breached a key financial covenant (Net Debt\u002FEBITDA ratio) at the standalone level, a critical risk highlighted by auditors in an \"Emphasis of Matter\".\n*   \u003Cb>Aggressive Accounting:\u003C\u002Fb> The company changed its Goodwill accounting policy to amortize over 99 years, a move that will cosmetically inflate future profits and was also highlighted by auditors.\n*   \u003Cb>Major Borrowing & Related Party Loan:\u003C\u002Fb> The Board approved a large CHF 200M loan from a promoter group entity and seeks to increase the company's total borrowing limit from ₹1,700 Cr to ₹4,000 Cr.",{"company_name":90,"filing_date":129,"filing_source":31,"headline":130,"id":131,"stock_code":75,"summary_text":132},"2026-05-19T23:41:41.113000","Consolidated Profit Masks Standalone Stress & Governance Red Flags","6a0ca839890e096a6fc5f9b0","*   \u003Cb>Standalone vs. Consolidated:\u003C\u002Fb> The parent company reported a Net Loss of ₹38.40 Cr, while the consolidated group reported a Net Profit of ₹97.45 Cr, highlighting severe financial stress at the standalone level.\n*   \u003Cb>Debt Covenant Breach:\u003C\u002Fb> The company breached financial covenants on multiple debt instruments at the standalone level, though it has received waivers from lenders.\n*   \u003Cb>Major Related-Party Loan:\u003C\u002Fb> The Board approved a plan to borrow up to CHF 200 million (approx. ₹2,452 Cr) from a promoter group company, pending shareholder approval.\n*   \u003Cb>Aggressive Accounting Change:\u003C\u002Fb> The company extended the useful life of its Goodwill to 99 years, an accounting change that boosts reported profits and was flagged by auditors in an \"Emphasis of Matter\".\n*   \u003Cb>Increased Borrowing Limit:\u003C\u002Fb> The company will seek shareholder approval to more than double its borrowing limit from ₹1,700 Cr to ₹4,000 Cr.",{"company_name":118,"filing_date":134,"filing_source":31,"headline":135,"id":136,"stock_code":26,"summary_text":137},"2026-05-19T23:41:41.109000","Posts Stellar FY26 Results with 37% Revenue Growth & Major Contract Wins","6a0ca8200c6b4fb98a9297d0","*   \u003Cb>Strong Financials:\u003C\u002Fb> Consolidated Revenue grew 36.7% YoY to ₹2,998 Cr, while Profit After Tax (PAT) rose 34.1% YoY to ₹723.8 Cr.\n*   \u003Cb>Digital Services Surge:\u003C\u002Fb> Revenue from the Digital Services segment skyrocketed by 114.4% YoY, driven by acquisitions and organic growth.\n*   \u003Cb>Core Business Profitability:\u003C\u002Fb> The Visa & Consular segment saw its EBITDA margin expand significantly to 40.1% from 34.5% in the previous year.\n*   \u003Cb>Landmark Contract Win:\u003C\u002Fb> Awarded a massive ₹2,055 Crore work order from UIDAI for managing Aadhaar Seva Kendras.\n*   \u003Cb>Healthy Balance Sheet:\u003C\u002Fb> The company holds a strong Net Cash position of ₹1,434 Crores and delivered a Return on Equity (ROE) of 29.4% for FY26.",{"company_name":139,"filing_date":140,"filing_source":31,"headline":141,"id":142,"stock_code":143,"summary_text":144},"AXIS Bank Ltd","2026-05-19T23:41:41.046000","Axis Bank Allots Equity Shares Under Employee Stock Option Plan","6a0ca803abd16353d20019d0","532215","*   The bank has allotted 257,834 equity shares of Rs. 2\u002F- each pursuant to the exercise of stock options by employees.\n*   As a result, the paid-up share capital has increased from Rs. 6,218,694,160 to Rs. 6,219,209,828.\n*   This action is a routine part of the bank's employee compensation and retention strategy.\n*   The issuance results in a minor equity dilution of approximately 0.0083% for existing shareholders.",{"company_name":22,"filing_date":146,"filing_source":9,"headline":147,"id":148,"stock_code":26,"summary_text":149},"2026-05-19T23:41:39.627000","Posts Strong FY26 Growth & Secures Landmark ₹2,055 Cr UIDAI Contract","6a0ca82ba157653c663a7b23","*   \u003Cb>FY26 Performance:\u003C\u002Fb> Revenue from operations grew by 36.7% YoY to ₹2,998 Cr, driven by strong performance across segments. Consolidated PAT increased by 34.1% YoY.\n*   \u003Cb>Landmark Contract Win:\u003C\u002Fb> Awarded a significant UIDAI work order worth ₹2,055 Crores for Aadhar Seva Kendras, providing strong future revenue visibility.\n*   \u003Cb>Segment Highlights:\u003C\u002Fb>\n    *   \u003Cb>Visa & Consular Services:\u003C\u002Fb> Remained the profit engine, contributing 90% of total EBITDA with a robust margin of 40.1%.\n    *   \u003Cb>Digital Services:\u003C\u002Fb> Revenue surged an exceptional 114.4% YoY. However, its EBITDA margin contracted sharply from 11.1% to 7.0%, a key monitorable.\n*   \u003Cb>Strong Financials & Outlook:\u003C\u002Fb> The company holds a Net Cash position of ₹1,434 Crores. Management has identified a major contract renewal pipeline of USD 1-2 Billion over the next two years.",{"company_name":151,"filing_date":152,"filing_source":31,"headline":153,"id":154,"stock_code":155,"summary_text":156},"John Cockerill India Ltd","2026-05-19T23:36:40.777000","Q4 FY26 Earnings Call Recording Now Available","6a0ca6ceecaa861d949281e7","500147","*   The company has published the audio recording of its earnings conference call held on May 19, 2026, for the quarter ended March 31, 2026.\n*   This filing is a procedural update to inform the stock exchange and does not contain any financial data itself.\n*   Investors can access the recording on the company's website to hear management's discussion and analysis of the financial results.\n*   This action complies with SEBI's disclosure requirements, enhancing transparency for shareholders.",{"company_name":83,"filing_date":158,"filing_source":9,"headline":159,"id":160,"stock_code":87,"summary_text":161},"2026-05-19T23:36:40.010000","[HCG Sharpens Oncology Focus with Strong FY26 Results and Milann Divestment]","6a0ca6fcabd16353d20019cb","*   **Strong Financial Performance (FY26):** Revenue grew 15% YoY to INR 25.5 Bn, with Adjusted EBITDA margin expanding to 18.5% (+68 bps).\n*   **Strategic Divestment:** Agreed to sell the non-core Milann fertility business for an enterprise value of INR 632 Mn to focus purely on the oncology business.\n*   **Governance Red Flag:** The buyer of the Milann business is an entity controlled by HCG's own Promoter and Chairman, making it a material related-party transaction requiring scrutiny.\n*   **Balance Sheet Strengthened:** Successfully raised INR 4,250 Mn via a rights issue, helping to significantly deleverage. The Net Debt\u002FEBITDA ratio improved from 2.27x to 0.98x.\n*   **Growth & Expansion:** Invested INR 2.9 Bn in capex, opened a new 110-bed facility in Bangalore, and plans to add over 200 more beds across its network.",{"company_name":22,"filing_date":163,"filing_source":9,"headline":164,"id":165,"stock_code":26,"summary_text":166},"2026-05-19T23:36:39.991000","FY26 Results: Record Revenue Driven by Digital Acquisition, Core Visa Business Boosts Profitability","6a0ca6ed0c6b4fb98a9297c9","*   \u003Cb>Record Performance:\u003C\u002Fb> The company achieved its highest-ever performance with FY26 revenue growing 36.7% YoY to ₹2,998.2 Cr and Profit After Tax (PAT) increasing by 34.1% YoY.\n*   \u003Cb>Digital Segment Surge:\u003C\u002Fb> Revenue from the Digital Business segment skyrocketed by 114.4% YoY, primarily driven by the consolidation of the newly acquired Aadifidelis Solutions.\n*   \u003Cb>Core Business Strength:\u003C\u002Fb> The high-margin Visa & Consular business showed robust health, with its EBITDA margin expanding significantly from 34.5% to 40.1% due to operational efficiencies.\n*   \u003Cb>Margin Dilution:\u003C\u002Fb> Despite record profits, the overall consolidated EBITDA margin contracted from 28.7% to 27.3%. This is a direct result of the rapid growth of the lower-margin (7.0%) Digital Business.\n*   \u003Cb>Shareholder Payout:\u003C\u002Fb> A final dividend of ₹0.5 per share was recommended, bringing the total dividend for FY26 to ₹2.5 per share (including the ₹2.0 interim dividend).",{"company_name":96,"filing_date":168,"filing_source":31,"headline":169,"id":170,"stock_code":87,"summary_text":171},"2026-05-19T23:31:41.351000","Posts Strong FY26 Results, Divests Fertility Business to Focus on Oncology","6a0ca5c5f43b112c8d9262c0","*   **Financial Performance:** FY26 revenue grew 15% YoY to ₹25.5 Bn, with Adjusted EBITDA up 19% to ₹4.7 Bn. EBITDA margin expanded to 18.5%.\n*   **Strategic Divestment:** Agreed to divest its non-core fertility business (Milann) for an enterprise value of ₹632 Mn to sharpen focus on its core oncology operations.\n*   \u003Cb>Key Consideration:\u003C\u002Fb> The buyer of the Milann business is an entity controlled by HCG's promoter, making this a significant related-party transaction.\n*   **Balance Sheet Strengthened:** Successfully raised ₹4,250 Mn via a rights issue, reducing the Net Debt\u002FEBITDA ratio to 0.98x from 2.27x in the prior year.\n*   **Growth & Expansion:** Commenced operations at the new 110-bed North Bangalore hospital and plans to add 200+ more beds across key locations.",{"company_name":173,"filing_date":174,"filing_source":31,"headline":175,"id":176,"stock_code":177,"summary_text":178},"Foseco India Ltd","2026-05-19T23:31:41.272000","FY25 BRSR: Strong ESG Progress & A Major Governance Red Flag","6a0ca5c358d87443453a6502","FOSECOIND","*   **Red Flag:** A sharp increase in investments in related parties to 100% of total investments in FY25 (from 0% in FY24) raises a significant governance concern.\n*   **ESG Goals:** The company has set a Net Zero Carbon target for 2050 and has already reduced CO2 emissions by 55%, far exceeding its 2025 goal of 20%.\n*   **Customer Complaints:** Customer complaints increased by 31% year-over-year to 204, though all were reportedly resolved.\n*   **Financials:** For FY25, the company reported a turnover of ₹60,402 Lakhs and a Net Worth of ₹1,03,930 Lakhs.\n*   **Compliance:** The company reported zero fines or penalties from any regulatory bodies for the financial year.",{"company_name":180,"filing_date":181,"filing_source":31,"headline":182,"id":183,"stock_code":184,"summary_text":185},"PI Industries Ltd","2026-05-19T23:31:41.120000","FY26 Results: Revenue & Profit Decline, JMD Resigns","6a0ca5e4bf8f716f130005bb","PIIND","*   FY26 consolidated revenue fell 15.9% to ₹67,137M and PAT dropped 20.5%, driven by a sharp downturn in the core Agro chemicals segment (-17.4% revenue).\n*   The Pharma segment showed strong growth, with revenue up 39.7%, though it remains loss-making.\n*   Mr. Rajnish Sarna has resigned as Joint Managing Director, citing health reasons. He will continue on the Board as a Non-Executive Director.\n*   The Board recommended a final dividend of ₹10\u002Fshare, bringing the total dividend for the year to ₹15\u002Fshare.\n*   Red flags include a significant drop in cash flow from operations and a ₹1,100M impairment charge on the investment in pharma subsidiary PI Health Sciences.\n*   Dr. Atul Kumar Gupta (CEO-CSM) was appointed as a Whole-time Director, signaling a strategic focus on the Custom Synthesis (CSM) business.",{"company_name":96,"filing_date":187,"filing_source":31,"headline":188,"id":189,"stock_code":87,"summary_text":190},"2026-05-19T23:31:41.041000","Reports Strong FY26 Results; Q4 Adjusted Profit Jumps 363%","6a0ca5b9c9cbead9b3c5e31d","*   FY26 revenue grew 15% YoY to ₹ 25,454 million, driven by strong demand for cancer care.\n*   Adjusted EBITDA for FY26 rose 19% YoY to ₹ 4,711 million, with margins expanding to 18.5%.\n*   \u003Cb>Q4 FY26 Adjusted PAT surged 363% YoY to ₹ 341 million\u003C\u002Fb>, aided by strong operational performance.\n*   Successfully completed a \u003Cb>Rights Issue, raising ₹ 4,250 million\u003C\u002Fb> to strengthen the balance sheet and fund future growth.\n*   Management expressed a positive outlook, focusing on a disciplined, returns-focused approach to growth.",{"company_name":192,"filing_date":193,"filing_source":31,"headline":194,"id":195,"stock_code":196,"summary_text":197},"Crompton Greaves Consumer Electricals Ltd","2026-05-19T23:31:41.023000","Q4 Revenue Jumps 11%; Launches Premium Brand 'Rhion' & Notes Butterfly Impairment","6a0ca5d3ecaa861d949281e2","CROMPTON","*   \u003Cb>Q4 Revenue Growth:\u003C\u002Fb> Consolidated revenue grew 11% YoY to ₹2,283 Crores, with EBITDA at ₹271 Crores (11.9% margin).\n*   \u003Cb>Butterfly Turnaround:\u003C\u002Fb> Subsidiary Butterfly Gandhimathi grew 17% YoY, turning cash-positive and signaling a successful turnaround.\n*   \u003Cb>New Premium Brand:\u003C\u002Fb> Announced the launch of 'Crompton Rhion', a new super-premium product line, to drive premiumization from the top down.\n*   \u003Cb>Butterfly Impairment:\u003C\u002Fb> Took a significant non-cash impairment on the carrying value of its investment in Butterfly. Management states this is an accounting entry with no cash flow impact but will affect ROCE.\n*   \u003Cb>Segment Strength:\u003C\u002Fb> Lighting business saw its best growth in 6 years (+14%), while Small Domestic Appliances grew ~30%.\n*   \u003Cb>Future Ambition:\u003C\u002Fb> Aims to build its Solar (Rooftop & Pumps) business into a ₹2,000 Crore portfolio in the next 3-4 years.",{"company_name":118,"filing_date":199,"filing_source":31,"headline":200,"id":201,"stock_code":26,"summary_text":202},"2026-05-19T23:31:40.955000","Management to Meet Investors on May 22","6a0ca5a1a157653c663a7b0e","*   The management will participate in a virtual group meeting with investors and analysts on May 22, 2026.\n*   The event, \"Nakshatra III – Shining Stars Amid Global Turbulence,\" is organized by Centrum.\n*   The company has confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the meeting.\n*   Discussions will be based on publicly available information from the company's website and stock exchange filings.",{"company_name":71,"filing_date":204,"filing_source":9,"headline":205,"id":206,"stock_code":75,"summary_text":207},"2026-05-19T23:31:39.761000","FY26 Profit Soars, Board Approves Major Debt Restructuring & Promoter Loan","6a0ca5dd890e096a6fc5f9a4","*   Consolidated Net Profit for FY26 surged by 2907% to ₹97.45 Crores, up from ₹3.24 Crores in the previous year.\n*   A stark contrast exists with the standalone entity, which reported a widening net loss and breached financial covenants (for which waivers were obtained from lenders).\n*   The Board approved raising an External Commercial Borrowing (ECB) of up to CHF 200 million from a promoter group entity owned by the Global MD, a material related-party transaction.\n*   A proposal to more than double the company's total borrowing limit from ₹1,700 Crores to ₹4,000 Crores will be presented to shareholders for approval.\n*   The company changed its accounting policy to extend the useful life of Goodwill to 99 years, which will cease amortization and boost future reported profits.",{"company_name":83,"filing_date":209,"filing_source":9,"headline":210,"id":211,"stock_code":87,"summary_text":212},"2026-05-19T23:31:39.738000","HCG Strengthens Leadership with New CFO and Key Appointments","6a0ca5b8abd16353d20019c0","*   \u003Cb>New CFO Appointed:\u003C\u002Fb> Mr. Sanjeev Kumar, former Group CFO of Medanta with over 30 years of experience, will take over as Chief Financial Officer (CFO) from May 25, 2026.\n*   \u003Cb>CEO Transition:\u003C\u002Fb> Dr. Manish Mattoo will cease to be the Interim CFO to focus on his role as CEO, marking a positive corporate governance step.\n*   \u003Cb>Investor Relations Head:\u003C\u002Fb> Mr. Ravi Gothwal, also formerly with Medanta, has been appointed as AVP – Investor Relations to enhance stakeholder communication.\n*   \u003Cb>Board Re-appointment:\u003C\u002Fb> Mr. Rajiv Maliwal has been re-appointed as a Non-Executive Independent Director for a second five-year term, subject to shareholder approval.",{"company_name":214,"filing_date":215,"filing_source":9,"headline":216,"id":217,"stock_code":196,"summary_text":218},"Crompton Greaves Consumer Electricals Limited","2026-05-19T23:31:39.684000","Q4 Surge: Crompton Posts 11% Growth, Unveils Premium 'Rhion' Line","6a0ca5d10c6b4fb98a9297c3","*   **Strong Q4 Performance:** Reported 11% YoY consolidated revenue growth to ₹2,283 Cr, with EBITDA margins at 11.9%.\n*   **Broad-Based Growth:** Saw significant growth across key segments, including Electrical Consumer Durables (10%), Lighting (14%), and a strong 17% growth in the Butterfly subsidiary.\n*   **Strategic Initiatives:** Launched 'Crompton Rhion', a new super-premium product line, and formally entered the Wires market to drive future growth.\n*   **Butterfly Turnaround:** The subsidiary's turnaround is on track, delivering strong growth with stable margins and becoming cash flow positive.\n*   **Key Accounting Note:** The company took a non-cash impairment on its Butterfly investment, a material accounting entry impacting ROCE.\n*   **Ambitious Outlook:** Aims to grow its Solar portfolio into a ₹2,000 Cr business over the next 3-4 years.",{"company_name":173,"filing_date":220,"filing_source":31,"headline":221,"id":222,"stock_code":177,"summary_text":223},"2026-05-19T23:26:41.311000","FY25 Annual Report: Major Acquisition & ₹25 Dividend Announced","6a0ca4e30c6b4fb98a9297be","*   \u003Cb>Major Acquisition:\u003C\u002Fb> Acquired a 75% stake in Foseco Crucible (India) Ltd, a transformative move to strengthen its presence in the non-ferrous segment. The deal was valued at ₹63,800.35 lakhs.\n*   \u003Cb>Financial Highlights (FY25):\u003C\u002Fb> Posted Consolidated Revenue of ₹64,341.85 lakhs and PAT of ₹7,486.82 lakhs, with the new subsidiary contributing significantly post-acquisition.\n*   \u003Cb>Shareholder Payout:\u003C\u002Fb> The Board has recommended a Final Dividend of ₹25 per share (250%) for the year ended Dec 31, 2025.\n*   \u003Cb>Key Red Flag:\u003C\u002Fb> Auditors flagged a compliance gap in IT controls, noting the accounting software's audit trail (edit log) feature was not enabled at the database level to log direct data changes.\n*   \u003Cb>Strategic Outlook:\u003C\u002Fb> Management is focused on integrating the new subsidiary to drive growth, leveraging combined R&D and customer reach.",{"company_name":225,"filing_date":226,"filing_source":31,"headline":227,"id":228,"stock_code":229,"summary_text":230},"SPEL Semiconductor Ltd","2026-05-19T23:26:41.260000","CFO Removed, Citing 'Continuous Absence'","6a0ca478a157653c663a7b07","517166","*   Mr. Thiruvenkatachari Parthasarathy has ceased to be the Chief Financial Officer (CFO) effective May 19, 2026.\n*   The company stated the reason for the change as \"Removal due to continuous absence from office,\" a significant governance red flag.\n*   The filing contains conflicting terms, referring to the departure as both a \"removal\" and a \"resignation,\" raising questions about the circumstances.\n*   This abrupt exit signals potential instability in senior management and raises concerns about the company's internal controls.",{"company_name":22,"filing_date":232,"filing_source":9,"headline":233,"id":234,"stock_code":26,"summary_text":235},"2026-05-19T23:26:39.931000","Announces Upcoming Investor & Analyst Meet","6a0ca481890e096a6fc5f99e","• A virtual group meeting with analysts and investors is scheduled for May 22, 2026.\n• The company has confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the event.\n• Discussions will be limited to information already available in the public domain, ensuring compliance with fair disclosure norms.",{"company_name":118,"filing_date":237,"filing_source":31,"headline":238,"id":239,"stock_code":26,"summary_text":240},"2026-05-19T23:21:41.154000","FY26 Results: Profit Soars 35%, Dividend Declared","6a0ca380bf8f716f130005b1","*   Reports strong FY26 results with a 36.7% rise in Revenue to ₹2,998 Cr and a 35.1% increase in Profit After Tax to ₹687 Cr.\n*   The Board has recommended a Final Dividend of ₹0.50 per share for the financial year 2025-26, subject to shareholder approval.\n*   Signals a major strategic pivot by re-allocating ₹13,800 lakhs of IPO proceeds towards the acquisition of Atyati Technologies, shifting focus from organic to inorganic growth in the digital services segment.\n*   Auditors flagged a key risk (\"Emphasis of Matter\") noting that subsidiary BLS E-Solutions Private Limited has not undertaken any revenue-generating activities since its government contract ended.",{"company_name":96,"filing_date":242,"filing_source":31,"headline":243,"id":244,"stock_code":87,"summary_text":245},"2026-05-19T23:21:41.148000","Hires New CFO & IR Head from Competitor Medanta","6a0ca35e5236ec99893a4a98","*   **New CFO:** Appointed Mr. Sanjeev Kumar as the new Chief Financial Officer (CFO), effective May 25, 2026. He was previously the Group CFO at InterGlobe Enterprises and CFO at Medanta, where he was instrumental in its successful IPO.\n*   **New IR Head:** Appointed Mr. Ravi Gothwal as AVP – Investor Relations. He also joins from Medanta, where he led Investor Relations and M&A.\n*   **Strategic Hires:** The hiring of both the new CFO and AVP-IR from a direct competitor, Medanta (Global Health Ltd), suggests a strategic focus on enhancing financial discipline and capital market engagement.\n*   **Leadership Transition:** Dr. Manish Mattoo will cease his role as Interim CFO and continue as the company's CEO, strengthening corporate governance by separating the two key positions.\n*   **Board Re-appointment:** The Board has approved the re-appointment of Mr. Rajiv Maliwal as a Non-Executive Independent Director for a second 5-year term, subject to shareholder approval.",{"company_name":118,"filing_date":247,"filing_source":31,"headline":248,"id":249,"stock_code":26,"summary_text":250},"2026-05-19T23:21:40.905000","Reports Strong FY26 Growth & Dividend; Auditor Flags Subsidiary Risk","6a0ca36d890e096a6fc5f998","*   Announced strong consolidated results for FY26 with a 37.6% YoY increase in revenue and a 34.1% YoY rise in profit.\n*   The Board recommended a final dividend of ₹0.50 per share, subject to shareholder approval.\n*   \u003Cb>Auditor's Red Flag:\u003C\u002Fb> An \"Emphasis of Matter\" was issued as a key subsidiary, BLS E-Solutions, currently has no revenue-generating activities, posing a risk to the Digital Services segment.\n*   \u003Cb>Strategic Pivot:\u003C\u002Fb> The company has significantly re-allocated IPO proceeds from organic growth and tech infrastructure towards a large acquisition (Atyati Technologies).\n*   Appointed Mr. Gaurav Aggarwal as President-Business Development and re-appointed an Independent Director, subject to approval.",{"company_name":252,"filing_date":253,"filing_source":31,"headline":254,"id":255,"stock_code":256,"summary_text":257},"Sasken Technologies Ltd","2026-05-19T23:21:40.904000","Scheduled Investor Meeting with NV Alpha Fund Management","6a0ca34b0c6b4fb98a9297b7","SASKEN","*   Sasken will hold an in-person meeting with institutional investor **NV Alpha Fund Management LLP** on **22nd May 2026**.\n*   This is a routine investor relations activity filed with the stock exchanges (BSE & NSE) as per SEBI regulations.\n*   The company has clarified that no unpublished price-sensitive information will be shared during the meeting.\n*   Discussions will be based on information already available in the public domain, such as the Q4 FY26 Investor Presentation.",{"company_name":225,"filing_date":259,"filing_source":31,"headline":260,"id":261,"stock_code":229,"summary_text":262},"2026-05-19T23:21:40.900000","Auditor Flags 'Going Concern' Risk Amidst Operational Shutdown & Deepening Losses","6a0ca36aabd16353d20019b2","*   **Auditor's Qualified Opinion:** The auditor has issued a qualified opinion, citing \"significant doubt\" about the company's ability to continue as a **going concern**.\n*   **Operations Halted:** The Board has approved the continued **suspension of factory operations** due to major machinery breakdowns and cessation of production.\n*   **Deepening Financial Crisis:** Net loss widened to ₹23.84 Cr, and **net worth (reserves) turned negative** at -₹43.07 Cr, driven by a massive inventory write-off of ₹19.63 Cr.\n*   **Management Turmoil:** The **CFO's services have been terminated**, and the company has witnessed the resignation of major employees.\n*   **Revenue Plummets:** Revenue from operations for FY26 **declined by 20.1%** year-over-year, indicating severe business disruption.",{"company_name":96,"filing_date":264,"filing_source":31,"headline":265,"id":266,"stock_code":87,"summary_text":267},"2026-05-19T23:21:40.771000","Announces Key Leadership Changes, Appoints New CFO","6a0ca36558d87443453a64f6","*   Appointed **Mr. Sanjeev Kumar as the new Chief Financial Officer (CFO)**, effective May 25, 2026. He previously served as Group CFO at competitor Medanta (Global Health Ltd.), where he was instrumental in their successful IPO.\n*   Appointed **Mr. Ravi Gothwal as AVP – Investor Relations**, also joining from Medanta, signaling a stronger focus on investor engagement.\n*   Re-appointed **Mr. Rajiv Maliwal** as a Non-Executive Independent Director for a second 5-year term, subject to shareholder approval.\n*   The Board meeting where these decisions were made lasted an **unusually long 11 hours**, suggesting significant strategic discussions were held.",{"company_name":269,"filing_date":270,"filing_source":9,"headline":271,"id":272,"stock_code":256,"summary_text":273},"Sasken Technologies Limited","2026-05-19T23:21:39.777000","Schedules Meeting with Institutional Investor","6a0ca354a157653c663a7afd","*   Sasken has scheduled an in-person meeting with institutional investor **NV Alpha Fund Management LLP**.\n*   The meeting will take place on **May 22, 2026**, at the company's registered office.\n*   The company has clarified that discussions will be based on publicly available information, and no new material information will be disclosed.",{"company_name":118,"filing_date":275,"filing_source":31,"headline":276,"id":277,"stock_code":26,"summary_text":278},"2026-05-19T23:16:41.310000","Reports Strong FY26 Growth, Declares Dividend & Shifts Strategy","6a0ca253a157653c663a7af8","*   **Strong Financials:** FY26 Consolidated Revenue grew 36.7% YoY to ₹2,998 Cr, while Profit After Tax (PAT) rose 34.1% YoY to ₹724 Cr. Basic EPS increased by 35.2% to ₹16.68.\n*   **Dividend Declared:** The Board has recommended a final dividend of ₹0.50 per equity share for the financial year 2025-26, subject to shareholder approval.\n*   **Major Strategic Pivot:** The company has re-allocated a significant portion of its IPO proceeds (₹13,800 Lakhs) to acquire Atyati Technologies, shifting its strategy from previously stated organic growth plans.\n*   **Key Appointment:** Mr. Gaurav Aggarwal has been appointed as President-Business Development to lead global projects and government outsourcing services.\n*   **Auditor Red Flag:** The auditor's report includes an \"Emphasis of Matter\" regarding a subsidiary, BLS E-Solutions Private Limited, which is currently non-operational as it has not undertaken any revenue-generating activities since its government contract ended.",{"company_name":225,"filing_date":280,"filing_source":31,"headline":281,"id":282,"stock_code":229,"summary_text":283},"2026-05-19T23:16:41.229000","Reports Alarming FY26 Results; Auditor Flags 'Going Concern' Risk","6a0ca252c9cbead9b3c5e307","*   **Going Concern Warning:** Auditor states a \"material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern.\"\n*   **Operations Halted:** Factory operations are suspended, and production was stopped in Q4 FY26 due to major machinery breakdown.\n*   **Financial Collapse:** Reported a net loss of ₹2,384 Lakhs and a 76% erosion in total equity. Cash balance is critically low at ₹0.11 Lakhs.\n*   **Management Turmoil:** The Board terminated the Chief Financial Officer (CFO), and the auditor noted the resignation of \"major employees.\"\n*   **Qualified Audit Opinion:** Statutory auditors issued a Qualified Opinion on the annual financial results, highlighting multiple severe issues.",{"company_name":96,"filing_date":285,"filing_source":31,"headline":286,"id":287,"stock_code":87,"summary_text":288},"2026-05-19T23:16:41.198000","Major Management Overhaul: HCG Appoints New CFO and IR Head from Competitor","6a0ca22decaa861d949281ce","*   Appointed a new CFO, Mr. Sanjeev Kumar, and a new Head of Investor Relations, Mr. Ravi Gothwal. Both are strategic hires from competitor Medanta (Global Health Ltd.), where they were instrumental in its successful IPO.\n*   This move strongly suggests HCG may be planning a significant strategic shift, a major fundraising round, or an effort to enhance its market perception.\n*   The company's CEO, Dr. Manish Mattoo, will no longer serve as the Interim CFO, which is a positive step for corporate governance and segregation of duties.\n*   A potential red flag was noted: the board meeting lasted an unusually long 11 hours, which could suggest extensive debate or discussion of other undisclosed strategic matters.",{"company_name":96,"filing_date":290,"filing_source":31,"headline":291,"id":292,"stock_code":87,"summary_text":293},"2026-05-19T23:16:41.174000","Announces Major Leadership Changes, Hires Key Executives from Competitor Medanta","6a0ca23babd16353d20019aa","*   **Appoints Mr. Sanjeev Kumar as the new permanent Chief Financial Officer (CFO).** He was previously the Group CFO at Medanta and was instrumental in its successful IPO.\n*   **Appoints Mr. Ravi Gothwal as AVP – Investor Relations.** He also joins from Medanta, where he led Investor Relations and M&A.\n*   **The hiring of a new CFO and Head of IR from a key competitor (Medanta) signals a strategic focus** on enhancing financial discipline and investor communication.\n*   **The company's CEO, Dr. Manish Mattoo, will cease to hold the additional position of Interim CFO,** a positive governance development.\n*   **Re-appoints Mr. Rajiv Maliwal** as a Non-Executive Independent Director for a second five-year term.",{"company_name":22,"filing_date":295,"filing_source":9,"headline":296,"id":297,"stock_code":26,"summary_text":298},"2026-05-19T23:16:40.889000","FY26 Results: 34% Profit Growth, Dividend Declared & Strategic Pivot","6a0ca254890e096a6fc5f993","*   **Strong Financials:** Full-year consolidated Profit After Tax (PAT) surged by 34.1% YoY to ₹723.8 crore, with revenue growing 36.7%.\n*   **Dividend Recommended:** The Board has proposed a final dividend of ₹0.50 per equity share for the financial year 2025-26.\n*   **Strategic Pivot:** The company is re-allocating IPO funds away from organic growth to fund the acquisition of Atyati Technologies, marking a significant strategic shift.\n*   **Auditor Red Flag:** The audit report includes an \"Emphasis of Matter\" on a subsidiary, BLS E-Solutions Private Limited, which has no revenue-generating activities, posing a notable risk.\n*   **Capital Allocation:** 56% of net IPO proceeds (₹155.2 crore) remain unutilized, now temporarily invested in bank deposits.",{"company_name":300,"filing_date":301,"filing_source":9,"headline":302,"id":303,"stock_code":304,"summary_text":305},"SKP Bearing Industries Limited","2026-05-19T23:16:40.774000","Board Meeting Scheduled to Approve Annual Financials","6a0ca21c0c6b4fb98a9297ac","SKP","*   A Board Meeting is scheduled for May 28, 2026, to consider and approve the company's audited financial results.\n*   The results cover the financial year ended March 31, 2026, and will include both Standalone and Consolidated figures.\n*   The approved financial results are expected to be publicly released around May 30, 2026.\n*   This is a significant event for shareholders to assess the company's full-year performance.",{"company_name":307,"filing_date":308,"filing_source":31,"headline":309,"id":310,"stock_code":311,"summary_text":312},"Vikran Engineering Ltd","2026-05-19T23:11:42.339000","Board to Consider Major Fundraising and Dividend","6a0ca0fbbf8f716f130005a4","544496","*   A Board Meeting is scheduled for Friday, 22nd May 2026, to approve financial results for the year ended 31st March 2026.\n*   The agenda includes considering a dividend for the Financial Year 2025-26.\n*   The Board will also consider a proposal to increase the company's borrowing limit by 50% from ₹1000 crore to ₹1500 crore.\n*   A separate proposal to raise funds up to ₹400 crore via non-convertible debentures (NCDs) or other debt securities will be discussed.",{"company_name":314,"filing_date":315,"filing_source":9,"headline":316,"id":317,"stock_code":184,"summary_text":318},"PI Industries Limited","2026-05-19T23:11:41.633000","FY26 Results: Core Agchem Dips, but Diversification into Pharma & Biologicals Shines","6a0ca12c0c6b4fb98a9297a7","• \u003Cb>Overall Performance:\u003C\u002Fb> FY26 revenue declined 16% to ₹67,137 Mn and Net Profit fell 20%, impacted by a global agchem downcycle.\n• \u003Cb>Core Business Challenge:\u003C\u002Fb> The key Agchem Exports segment suffered a significant 17.7% revenue drop.\n• \u003Cb>Diversification Success:\u003C\u002Fb> The Health Sciences (Pharma) segment was a major bright spot, with revenue growing 40% YoY and losses narrowing significantly.\n• \u003Cb>Margin Strength:\u003C\u002Fb> Despite lower revenue, consolidated Gross Margin improved by over 500 bps to 58%, showcasing strong cost discipline.\n• \u003Cb>Strategic Milestones:\u003C\u002Fb> Achieved a critical US EPA approval for a Bionematocide and became the first Indian company to innovate the \"PIOXANILIPROLE\" molecule.\n• \u003Cb>Shareholder Return:\u003C\u002Fb> The Board approved a final dividend of ₹10 per share, bringing the total for FY26 to ₹15 per share.\n• \u003Cb>Outlook:\u003C\u002Fb> Management remains positive for growth in FY27, expecting an acceleration in Exports and continued momentum in Pharma.",{"company_name":320,"filing_date":321,"filing_source":9,"headline":322,"id":323,"stock_code":324,"summary_text":325},"NGL Fine-Chem Limited","2026-05-19T23:11:41.391000","Earnings Call Announcement for Q4 & FY26 Results","6a0ca0f7a157653c663a7af0","NGLFINE","*   An Earnings Conference Call is scheduled for **Monday, May 25, 2026, at 12:00 PM (IST)**.\n*   The call will discuss the company's operational and financial performance for the fourth quarter and full financial year 2026 (Q4 & FY26).\n*   Key management, including the Managing Director (Mr. Rahul Nachane) and CFO (Mr. Rajesh Lawande), will be present.\n*   This filing is an intimation and does not contain any financial results; those will be discussed during the call.",{"company_name":327,"filing_date":328,"filing_source":9,"headline":329,"id":330,"stock_code":331,"summary_text":332},"Sirca Paints India Limited","2026-05-19T23:11:41.374000","Sirca Paints FY26: Profit Soars 32.5%, Board Recommends ₹2 Dividend","6a0ca11babd16353d20019a4","SIRCA","- **Strong FY26 Performance:** Revenue grew 31.8% YoY to ₹492.5 Cr, and Net Profit rose 32.5% to ₹65 Cr.\n- **Shareholder Payout:** The Board recommended a final dividend of \u003Cb>₹2 per share\u003C\u002Fb> for FY26, pending shareholder approval at the upcoming AGM.\n- **Earnings Growth:** Basic Earnings Per Share (EPS) increased by nearly 30% to ₹11.63 from ₹8.95 in the previous year.\n- **Key Concern:** Despite strong profit growth, operating cash flow declined. This was driven by a significant increase in trade receivables, posing a potential risk to working capital management.",{"company_name":83,"filing_date":334,"filing_source":9,"headline":335,"id":336,"stock_code":87,"summary_text":337},"2026-05-19T23:11:41.244000","HCG to Sell Fertility Business for ₹37.64 Crore in Related-Party Deal","6a0ca106890e096a6fc5f98b","*   The Board has approved the sale of its entire stake in its non-core subsidiary, BACC Health Care Private Limited (a fertility and reproductive healthcare business).\n*   The total sale consideration is ₹37.64 crore, which will be used to reinvest in the company's core cancer services business.\n*   The buyer is Inviga Healthcare Fund I, a fund controlled by HCG's own Promoter and Chairman, Dr. B.S. Ajaikumar.\n*   The company has justified the related-party transaction by stating it is on an \"arm's length basis,\" was approved by the Audit Committee, and is based on an independent valuation.",{"company_name":96,"filing_date":339,"filing_source":31,"headline":340,"id":341,"stock_code":87,"summary_text":342},"2026-05-19T23:06:41.148000","[HCG Divests Non-Core Fertility Arm for ₹37.64 Cr]","6a0c9fd4ecaa861d949281bf","*   HCG will sell its entire stake in BACC Health Care Private Limited, its non-core fertility business, for a total of ₹37.64 crores.\n*   The divestment aligns with HCG's strategy to focus on its core cancer services and reinvest the capital into high-growth areas.\n*   The buyer is Inviga Healthcare Fund I, an entity controlled by HCG's own Chairman, Dr. B.S. Ajaikumar, making this a related party transaction.\n*   HCG states the deal was approved by the Audit Committee, conducted via a competitive process, and is on an arm's length basis, backed by an independent valuation.",{"company_name":344,"filing_date":345,"filing_source":31,"headline":346,"id":347,"stock_code":324,"summary_text":348},"NGL Fine Chem Ltd","2026-05-19T23:06:41.140000","Mark Your Calendars: Q4 & FY26 Earnings Call Announced!","6a0c9fcac9cbead9b3c5e2fc","*   The company will host an Earnings Conference Call to discuss its financial and operational performance for Q4 & FY26.\n*   **Date & Time:** Monday, May 25, 2026, at 12:00 PM (IST).\n*   Key management, including Mr. Rahul Nachane (Managing Director) and Mr. Rajesh Lawande (CFO), will be present.\n*   The company has confirmed that no unpublished price-sensitive information (UPSI) will be disclosed during the call.",{"company_name":180,"filing_date":350,"filing_source":31,"headline":351,"id":352,"stock_code":184,"summary_text":353},"2026-05-19T23:06:40.891000","FY26 Revenue Declines 16% Amid Agchem Downturn; Pharma Segment Surges 40%","6a0c9ff5bf8f716f1300059f","*   \u003Cb>FY26 Performance:\u003C\u002Fb> Consolidated revenue fell 16% YoY to ₹67,137 Mn, while reported net profit declined 20% to ₹13,208 Mn.\n*   \u003Cb>Core Business Impact:\u003C\u002Fb> The Agchem Exports segment, the company's largest, saw a 19.7% revenue drop due to a global industry slowdown and destocking.\n*   \u003Cb>Diversification Shines:\u003C\u002Fb> The Pharma segment was a key growth driver, with revenue surging 40% YoY, driven by new customer acquisition.\n*   \u003Cb>Profit Analysis:\u003C\u002Fb> Reported net profit was boosted by an exceptional income of ₹1,260 Mn. Excluding this, the adjusted profit decline was a steeper ~27%.\n*   \u003Cb>Shareholder Payout:\u003C\u002Fb> The Board has recommended a final dividend of ₹10 per share, bringing the total dividend for FY26 to ₹15 per share.\n*   \u003Cb>Outlook:\u003C\u002Fb> Management remains positive for growth in FY27, citing a strong order book for exports and continued momentum in the Pharma business.",{"company_name":22,"filing_date":355,"filing_source":9,"headline":356,"id":357,"stock_code":26,"summary_text":358},"2026-05-19T23:06:40.195000","FY26 Results: Revenue Jumps 37%, Dividend Declared, Auditor Flags Concern","6a0c9fe50c6b4fb98a9297a0","*   **Strong Financials:** FY26 consolidated revenue grew 36.7% YoY to ₹2,99,821 Lakhs, with Profit After Tax (PAT) up 34.1% to ₹72,380 Lakhs.\n*   **Dividend Declared:** The Board has recommended a final dividend of ₹0.50 per equity share, subject to shareholder approval.\n*   **Auditor's Red Flag:** The auditor's report included an \"Emphasis of Matter\" highlighting that a subsidiary, BLS E-Solutions Private Limited, has no revenue-generating activities after its government contract ended.\n*   **Strategic Pivot:** The company altered the use of IPO proceeds, re-allocating funds originally meant for organic growth (\"BLS Stores\") to help fund the acquisition of Atyati Technologies.\n*   **Management Update:** Appointed Mr. Gaurav Aggarwal as President-Business Development.",{"company_name":360,"filing_date":361,"filing_source":9,"headline":362,"id":363,"stock_code":364,"summary_text":365},"Banswara Syntex Limited","2026-05-19T23:06:40.141000","Board Confirms Auditor Re-appointments for FY 2026-27","6a0c9fc8890e096a6fc5f982","BANSWRAS","*   The Board of Directors has approved the re-appointment of the company's Cost and Internal Auditors.\n*   \u003Cb>Cost Auditors:\u003C\u002Fb> M\u002Fs. K.G. Goyal & Company re-appointed.\n*   \u003Cb>Internal Auditor:\u003C\u002Fb> M\u002Fs. Ankit Maheshwari & Associates re-appointed.\n*   Both appointments are for a 12-month term, effective from April 1, 2026.",{"company_name":367,"filing_date":368,"filing_source":9,"headline":369,"id":370,"stock_code":177,"summary_text":371},"Foseco India Limited","2026-05-19T23:06:40.103000","[Foseco India Proposes ₹25 Dividend and Re-appointment of MD & CEO]","6a0c9fe0a157653c663a7ae7","*   **Strong FY25 Performance**: The company reported consistent growth with Total Revenue from Operations at ₹60,401.65 lakhs and Net Profit After Tax at ₹7,521.74 lakhs.\n*   **Dividend Proposed**: The Board has recommended a Final Dividend of ₹25 per share (250%) for the financial year ended December 31, 2025. The record date is set for June 3, 2026.\n*   **Leadership Continuity**: Shareholder approval is sought for the re-appointment of Prasad Chavare as Managing Director & CEO for a 5-year term and Amitabha Mukhopadhyay as an Independent Director for a second 5-year term.\n*   **Action for Physical Shareholders**: A special one-year window from February 5, 2026, to February 4, 2027, is available to facilitate the transfer and dematerialization of physical shares purchased before April 1, 2019.",{"company_name":373,"filing_date":374,"filing_source":9,"headline":375,"id":376,"stock_code":377,"summary_text":378},"Valiant Organics Limited","2026-05-19T23:06:40.101000","Proposes Sale of Subsidiary in Related-Party Transaction","6a0c9fd3abd16353d200199d","VALIANTORG","*   Announced the sale and disposal of its partnership interest in its subsidiary, Dhanvallabh Ventures LLP (DVLLP).\n*   In return, the company will receive 1,86,07,531 equity shares of Valiant Laboratories Limited.\n*   This is a Related-Party Transaction, as the Promoter Group holds a significant interest (>20%) in the counterparty (DVLLP).\n*   **Red Flag:** The filing shows a major discrepancy in the consideration amount, listing both ₹38 Lakhs and 1.86 crore shares.\n*   The transaction is contingent upon receiving shareholder approval.",{"company_name":118,"filing_date":380,"filing_source":31,"headline":381,"id":382,"stock_code":26,"summary_text":383},"2026-05-19T23:01:40.655000","Posts Strong FY26 Results & Recommends Dividend","6a0c9ebbc9cbead9b3c5e2f7","*   \u003Cb>Financials (FY26):\u003C\u002Fb> Revenue grew 36% YoY to ₹3,09,337 lakhs, and Profit After Tax (PAT) rose 34.1% to ₹72,380 lakhs. Basic EPS increased to ₹16.68.\n*   \u003Cb>Dividend:\u003C\u002Fb> The Board recommended a final dividend of ₹0.50 per share (50%), subject to shareholder approval.\n*   \u003Cb>Management Update:\u003C\u002Fb> Appointed Mr. Gaurav Aggarwal as President-Business Development to drive growth.\n*   \u003Cb>Auditor's Notes & Risks:\u003C\u002Fb> An \"Emphasis of Matter\" was raised for a subsidiary with no revenue-generating activity. The financials for 48 subsidiaries also remain unaudited.\n*   \u003Cb>Strategic Shift:\u003C\u002Fb> The company altered the use of its IPO proceeds after receiving shareholder approval, re-allocating funds previously marked for organic growth.",{"company_name":385,"filing_date":386,"filing_source":31,"headline":387,"id":388,"stock_code":377,"summary_text":389},"Valiant Organics Ltd","2026-05-19T23:01:40.564000","Board Approves Strategic Divestment from Subsidiary","6a0c9eaf58d87443453a64d9","*   The Board has approved exiting its partnership in subsidiary **Dhanvallabh Ventures LLP (DVLLP)**, which will cease to be a subsidiary post-transaction.\n*   In a non-cash deal, the company will receive **1,86,07,531 equity shares of Valiant Laboratories Limited** as consideration.\n*   The transaction is classified as a **Material Related Party Transaction** and requires **shareholder approval** via a special resolution to proceed.\n*   DVLLP contributes a significant **11.34% to the company's net worth** but a negligible **0.05% to its turnover**, suggesting it is primarily an asset-holding entity.",{"company_name":360,"filing_date":391,"filing_source":9,"headline":392,"id":393,"stock_code":364,"summary_text":394},"2026-05-19T23:01:39.944000","Welcomes New Independent Director & Reappoints Key Executives","6a0c9e9e0c6b4fb98a929798","*   The company has re-appointed its Managing Director, Mr. Shaleen Toshniwal, and two Executive Directors, ensuring management continuity and operational stability.\n*   **Mr. Udeypaul Singh Gill** has been appointed as a new **Non-Executive Independent Director**, effective May 20, 2026.\n*   Mr. Gill is a highly experienced industry leader with over four decades in textiles and noted expertise in sustainability, carbon neutrality, and strategic innovation.\n*   His appointment is seen as a significant positive for corporate governance and signals a potential strategic focus on ESG initiatives.",{"company_name":360,"filing_date":396,"filing_source":9,"headline":397,"id":398,"stock_code":364,"summary_text":399},"2026-05-19T23:01:39.928000","Appoints New Registrar & Share Transfer Agent","6a0c9e9f890e096a6fc5f97b","*   Banswara Syntex has appointed M\u002Fs. Bigshare Services Private Limited as its new Registrar and Share Transfer Agent (RTA), effective 19 May 2026.\n*   This is a key update for shareholders, as all future services related to share transfers, dematerialization, and dividend processing will now be handled by Bigshare Services.\n*   The appointment is a standard governance measure to ensure efficient shareholder services.",{"company_name":401,"filing_date":402,"filing_source":9,"headline":403,"id":404,"stock_code":405,"summary_text":406},"Remsons Industries Limited","2026-05-19T23:01:39.907000","Board Meeting on May 22 to Decide on Final Dividend & ESOP","6a0c9e9ea157653c663a7adf","REMSONSIND","*   A Board of Directors meeting is scheduled for May 22, 2026, to consider and approve the annual financial results for the year ended March 2026.\n*   The Board will also consider a recommendation for a final dividend for the financial year 2025-26.\n*   A proposal for an Employee Stock Option Plan (ESOP) is on the agenda, which could lead to potential equity dilution for shareholders.\n*   Investors should monitor the outcome of this meeting for key decisions on financial performance, dividend payout, and the ESOP scheme.",{"company_name":96,"filing_date":408,"filing_source":31,"headline":409,"id":410,"stock_code":87,"summary_text":411},"2026-05-19T22:56:40.955000","FY26 Results: Strategic Divestment & Capital Raise Amidst Profit Decline","6a0c9da2bf8f716f13000594","*   \u003Cb>FY26 Performance:\u003C\u002Fb> Revenue grew 14.4% YoY to ₹253,843 lakhs, but Profit After Tax (PAT) declined 53.3% due to significant impairment charges.\n*   \u003Cb>Strategic Divestment:\u003C\u002Fb> Approved the sale of its non-core fertility business (BACC Health Care) for ~₹37.6 crores in a related-party transaction.\n*   \u003Cb>Capital Raise:\u003C\u002Fb> Successfully raised ~₹42,468 lakhs via a rights issue; the funds are currently unutilised and await deployment.\n*   \u003Cb>Management Update:\u003C\u002Fb> Appointed Mr. Sanjeev Kumar as the new Chief Financial Officer (CFO), effective May 25, 2026.\n*   \u003Cb>Clean Audit:\u003C\u002Fb> Received an unmodified (clean) opinion from statutory auditors on the annual financial results.",{"company_name":413,"filing_date":414,"filing_source":31,"headline":415,"id":416,"stock_code":417,"summary_text":418},"Olympic Cards Ltd","2026-05-19T22:56:40.772000","[Compliance Report Flags Late Fees & Pending Penalties]","6a0c9d8758d87443453a64d3","534190","*   The Annual Secretarial Compliance Report for FY26 revealed a failure to pay annual listing fees on time for the previous year, resulting in a fine. This was noted as a recurring issue.\n*   \u003Cb>RED FLAG:\u003C\u002Fb> The company is awaiting a decision from the BSE on waiver applications for multiple penalties levied for past non-compliances, totaling over ₹5.14 Lakhs.\n*   These penalties stem from various violations of SEBI regulations dating back to 2020 and 2024, creating significant regulatory uncertainty.\n*   The report otherwise confirmed general compliance with Secretarial Standards but contained no material updates on financials, operations, or business strategy.",{"company_name":173,"filing_date":420,"filing_source":31,"headline":421,"id":422,"stock_code":177,"summary_text":423},"2026-05-19T22:56:40.760000","AGM Notice: Proposes ₹25\u002Fshare Dividend & Key Appointments","6a0c9d8ac9cbead9b3c5e2f1","*   The Board has recommended a final dividend of ₹25 per share (250%) for FY25, with a record date of June 3, 2026.\n*   For FY25, the company reported a 15.1% YoY increase in revenue to ₹60,401.65 lakhs and a 3% rise in Net Profit to ₹7,521.74 lakhs.\n*   The company seeks shareholder approval for the re-appointment of Mr. Prasad Chavare as Managing Director & CEO for a second 5-year term.\n*   A special one-year window (Feb 5, 2026 - Feb 4, 2027) is available for shareholders to transfer or dematerialize physical shares purchased before April 1, 2019.",{"company_name":425,"filing_date":426,"filing_source":31,"headline":427,"id":428,"stock_code":429,"summary_text":430},"IDBI Bank Ltd","2026-05-19T22:56:40.714000","Leadership Update: Deputy Managing Director Re-appointed","6a0c9d750c6b4fb98a92978f","IDBI","*   The Board of Directors has approved the re-appointment of Shri Jayakumar S. Pillai as Deputy Managing Director (DMD).\n*   The re-appointment is for a period of one year, effective from June 12, 2026, and is based on approval from the Reserve Bank of India (RBI).\n*   Shri Pillai has over 33 years of banking experience and oversees critical functions including Corporate Business, IT, HR, and Finance.\n*   **Key takeaway for investors:** The short one-year tenure is a notable point, potentially indicating a transitional arrangement.",{"company_name":432,"filing_date":433,"filing_source":9,"headline":434,"id":435,"stock_code":429,"summary_text":436},"IDBI Bank Limited","2026-05-19T22:56:40.309000","IDBI Bank Re-appoints Deputy Managing Director","6a0c9d76a157653c663a7ad6","*   The Board has approved the re-appointment of **Shri Jayakumar S. Pillai** as **Deputy Managing Director (DMD)**.\n*   The re-appointment is for a period of **one year**, effective from **June 12, 2026**.\n*   This decision, approved by the RBI, ensures leadership continuity across critical functions including Corporate Business, IT, Finance, and HR.\n*   Shri Pillai has over 33 years of experience in commercial banking and holds several key responsibilities within the bank.",{"company_name":373,"filing_date":438,"filing_source":9,"headline":439,"id":440,"stock_code":377,"summary_text":441},"2026-05-19T22:56:40.306000","Board Approves Strategic Divestment of Subsidiary","6a0c9d7eabd16353d200198d","*   The Board has approved a proposal for Valiant Organics to cease being a partner in its subsidiary, Dhanvallabh Ventures LLP (DVLLP).\n*   In exchange, Valiant Organics will receive 1,86,07,531 equity shares of Valiant Laboratories Limited, instead of cash.\n*   This transaction is classified as a material related party transaction and will result in DVLLP no longer being a subsidiary.\n*   The proposal is subject to shareholder approval through a special resolution.",{"company_name":443,"filing_date":444,"filing_source":9,"headline":445,"id":446,"stock_code":447,"summary_text":448},"Siyaram Silk Mills Limited","2026-05-19T22:56:40.294000","Q4 FY26 Results & Dividend Discrepancy","6a0c9d85890e096a6fc5f973","SIYSIL","*   \u003Cb>Q4 FY26 Performance:\u003C\u002Fb> The company reported a total income of ₹871.0 crores for the quarter, with the Fabric segment contributing 80% of revenue.\n*   \u003Cb>Dividend Declared:\u003C\u002Fb> A special interim dividend of ₹4\u002Fshare and a recommended final dividend of ₹5\u002Fshare were announced for the financial year 2025-26.\n*   \u003Cb>Key Discrepancy:\u003C\u002Fb> The filing states a total dividend of ₹16 per share for the year, but the announced components only sum to ₹9 per share. This is a significant and unexplained discrepancy.\n*   \u003Cb>Management Outlook:\u003C\u002Fb> The company is \"cautiously optimistic\" about long-term growth but acknowledges near-term risks from inflation, geopolitical issues, and an extended heatwave.",{"company_name":450,"filing_date":451,"filing_source":31,"headline":452,"id":453,"stock_code":454,"summary_text":455},"Bluspring Enterprises Ltd","2026-05-19T22:51:41.234000","Allots 28,819 Equity Shares Under Stock Ownership Plan","6a0c9c4c58d87443453a64cd","BLUSPRING","*   The company has allotted 28,819 new equity shares to eligible employees who exercised their options under the \"Special Purpose Stock Ownership Plan 2025\".\n*   This action increases the total number of equity shares to 14,94,40,980 and the paid-up share capital to Rs. 1,49,44,09,800.\n*   The allotment results in a minor equity dilution of approximately 0.019% for existing shareholders.\n*   An application will be made to the BSE and NSE for the listing and trading of these new shares.",{"company_name":457,"filing_date":458,"filing_source":31,"headline":459,"id":460,"stock_code":461,"summary_text":462},"Innovassynth Technologies (India) Ltd","2026-05-19T22:51:41.233000","Raises ₹69.65 Crore in Oversubscribed Rights Issue","6a0c9c50c9cbead9b3c5e2eb","533315","*   The company has successfully allotted 1,74,11,380 new equity shares pursuant to its Rights Issue.\n*   A total of ₹69.65 Crores was raised at an issue price of ₹40 per share.\n*   The issue was heavily oversubscribed by 155.29%, indicating strong investor demand.\n*   Following the allotment, the company's paid-up equity share capital has increased from ₹75.45 Crores to ₹92.86 Crores.",{"company_name":464,"filing_date":465,"filing_source":31,"headline":466,"id":467,"stock_code":447,"summary_text":468},"Siyaram Silk Mills Ltd","2026-05-19T22:51:41.025000","Posts Strong FY26 Results & Announces ₹16\u002FShare Dividend","6a0c9c59f43b112c8d926295","*   \u003Cb>Strong Q4 FY26 Growth:\u003C\u002Fb> Revenue rose 16.1% YoY to ₹871 Cr, with Profit After Tax (PAT) surging 30.6% YoY to ₹95 Cr.\n*   \u003Cb>Solid Full-Year Results:\u003C\u002Fb> For FY26, total income grew 16% to ₹2,653 Cr, and PAT increased by 15% to ₹228 Cr.\n*   \u003Cb>Significant Dividend Payout:\u003C\u002Fb> A total dividend of ₹16 per share has been declared\u002Frecommended for FY26.\n*   \u003Cb>Key Business Driver:\u003C\u002Fb> The Fabric segment continues to be the primary revenue source, accounting for 80% of Q4 income.\n*   \u003Cb>Cautious Outlook:\u003C\u002Fb> Management remains optimistic but notes potential risks from inflation, geopolitical issues, and extreme weather.",{"company_name":470,"filing_date":471,"filing_source":9,"headline":472,"id":473,"stock_code":474,"summary_text":475},"HEC Infra Projects Limited","2026-05-19T22:51:40.094000","Wins ₹11.48 Crore Contract from POWERGRID","6a0c9c47ecaa861d949281ac","HECPROJECT","*   **New Order:** The company has secured a new contract from **Power Grid Corporation of India Limited (POWERGRID)**.\n*   **Contract Value:** The total value of the order is **₹ 11.48 Crores**.\n*   **Project Scope:** The work involves the supply, erection, testing, and commissioning for the augmentation of transformation capacity at the 400\u002F220 kV Neemrana (PG) Substation.\n*   **Timeline:** The project is to be completed within **15 months**.",{"company_name":477,"filing_date":478,"filing_source":9,"headline":479,"id":480,"stock_code":481,"summary_text":482},"Mayur Uniquoters Ltd","2026-05-19T22:51:39.903000","Confirms Auditor Appointments for FY 2026-27","6a0c9c41abd16353d2001984","MAYURUNIQ","• The Board of Directors has approved the re-appointment of the company's Cost and Internal Auditors.\n• **M\u002Fs. PAVAN GUPTA & ASSOCIATES** will continue as the Cost Auditors for the financial year 2026-2027.\n• **M\u002Fs. S.Bhandari & Company LLP** will continue as the Internal Auditor for the financial year 2026-2027.\n• Both appointments are effective from April 1, 2026, ensuring continuity in audit and oversight functions.",{"company_name":484,"filing_date":485,"filing_source":9,"headline":486,"id":487,"stock_code":454,"summary_text":488},"Bluspring Enterprises Limited","2026-05-19T22:51:39.880000","Allots Equity Shares Under Employee Stock Plan","6a0c9c44a157653c663a7acd","*   Allotted **28,819 new equity shares** to employees who exercised their Restricted Stock Units (RSUs).\n*   This action was taken under the \"Special Purpose Stock Ownership Plan 2025\" and approved by the Nomination and Remuneration Committee on May 19, 2026.\n*   The company's total paid-up share capital has increased from 14,94,12,161 shares to **14,94,40,980 shares**.\n*   The new shares will rank equally with existing equity shares. This results in a minor equity dilution of approximately **0.019%**.",{"company_name":484,"filing_date":490,"filing_source":9,"headline":491,"id":492,"stock_code":454,"summary_text":493},"2026-05-19T22:51:39.858000","Allots New Shares Under Employee Stock Plan","6a0c9c4a890e096a6fc5f96c","*   Allotted 288,190 new equity shares to employees exercising their options under the company's ESOP.\n*   Total shares outstanding have increased to 1,494,409,800, resulting in a minor equity dilution of approximately 0.019%.\n*   The filing highlights that the company has recently transitioned from an unlisted to a listed entity.",{"company_name":360,"filing_date":495,"filing_source":9,"headline":496,"id":497,"stock_code":364,"summary_text":498},"2026-05-19T22:51:39.801000","Board Recommends ₹1 Final Dividend for FY26","6a0c9c440c6b4fb98a929786","*   The Board of Directors has recommended a Final Dividend of ₹1 per equity share for the financial year 2025-2026.\n*   This represents a 20% payout on the share's face value of ₹5.\n*   The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM).\n*   The Record Date and Payment Date will be announced separately.",{"company_name":450,"filing_date":500,"filing_source":31,"headline":501,"id":502,"stock_code":454,"summary_text":503},"2026-05-19T22:47:01.514000","Gets Clean Chit on Annual Compliance for FY26","6a0c9b4358d87443453a64c8","- Received a clean Annual Secretarial Compliance Report for the financial year ended March 31, 2026, with **no instances of non-compliance** reported by the independent Practicing Company Secretary.\n- Confirmed that **no actions were taken against the company**, its directors, or subsidiaries by SEBI or Stock Exchanges during the review period.\n- Key governance indicators were strong: no statutory auditor resigned, all related party transactions were pre-approved by the Audit Committee, and board evaluations were conducted.\n- Identified four material subsidiaries for FY26: Monster.com (India), Vedang Gellular Services, Terrier Security Services (India), and Trimax Smart Infraprojects.",{"company_name":96,"filing_date":505,"filing_source":31,"headline":506,"id":507,"stock_code":87,"summary_text":508},"2026-05-19T22:47:01.369000","Strategic Overhaul: HCG Sells Subsidiary, Raises Capital for Oncology Focus","6a0c9b59c9cbead9b3c5e2e6","• **Strategic Shift:** Divesting its non-core fertility business (BACC Health Care) for ₹37.64 Crores to double down on its core oncology business.\n• **Capital Boost:** Raised over ₹424 Crores via a rights issue, strengthening the balance sheet to fund growth in cancer care.\n• **Profit Hit:** Consolidated profit fell sharply by 69% to ₹1,376 lakhs, dragged down by significant impairment charges on the divested unit and another subsidiary.\n• **New Leadership:** Appointed a new Chief Financial Officer, Mr. Sanjeev Kumar, effective May 25, 2026.",{"company_name":464,"filing_date":510,"filing_source":31,"headline":511,"id":512,"stock_code":447,"summary_text":513},"2026-05-19T22:47:01.189000","Announces 200% Special Interim Dividend","6a0c9b33ecaa861d949281a1","*   The Board has declared a **Special Interim Dividend** of **₹ 4\u002F-** per equity share for the financial year ending 31st March, 2026.\n*   This represents a **200%** dividend on the share's face value of ₹ 2\u002F-.\n*   The **Record Date** to determine shareholder eligibility is **Monday, 25th May, 2026**.",{"company_name":515,"filing_date":516,"filing_source":31,"headline":517,"id":518,"stock_code":519,"summary_text":520},"Tamilnadu Petroproducts Ltd","2026-05-19T22:47:01.188000","Posts Strong Yearly Profit Growth Despite a Disastrous Q4","6a0c9b44bf8f716f13000587","TNPETRO","- **FY26 Performance:** Full-year revenue fell 19.37% to ₹1,489 Cr, but Net Profit surged 72.62% YoY to ₹88.76 Cr, driven by strong cost controls.\n- **Q4 FY26 Collapse:** The fourth quarter saw a severe downturn, with revenue plummeting 72.61% YoY. Profit Before Tax (before exceptional items) was nearly wiped out, falling 99.5% to just ₹0.11 Cr.\n- **Dividend Increase:** The Board has recommended a higher dividend of ₹1.50 per share (15%), an increase from the 12% paid in the previous year, subject to shareholder approval.\n- **Management Insight:** Management attributed the poor Q4 to a \"sharp increase in raw material costs\" but highlighted strong manufacturing efficiency for the full-year performance.\n- **Exceptional Item:** Q4 profit was significantly supported by an exceptional income of ₹7.62 Cr from an insurance claim related to the Michaung cyclone.",{"company_name":457,"filing_date":522,"filing_source":31,"headline":523,"id":524,"stock_code":461,"summary_text":525},"2026-05-19T22:47:01.175000","Successfully Raises ₹69.64 Crore via Oversubscribed Rights Issue","6a0c9b3ba157653c663a7ac6","*   The company has successfully completed its Rights Issue, raising a total of ₹ 69.64 Crores.\n*   It has allotted 1,74,11,380 new equity shares at an issue price of ₹ 40 per share.\n*   The issue was heavily oversubscribed, receiving 155.29% subscription, which indicates strong investor confidence.\n*   As a result, the company's paid-up equity share capital has increased to ₹ 92.86 Crores from ₹ 75.44 Crores.",{"company_name":83,"filing_date":527,"filing_source":9,"headline":528,"id":529,"stock_code":87,"summary_text":530},"2026-05-19T22:46:41.442000","FY26 Results: HCG Divests Fertility Business, Appoints New CFO","6a0c9b540c6b4fb98a929781","*   \u003Cb>Consolidated Revenue:\u003C\u002Fb> Grew 14.4% YoY to ₹253,843 Lakhs.\n*   \u003Cb>Consolidated Profit:\u003C\u002Fb> Dropped 53.4% YoY to ₹2,278 Lakhs, impacted by an exceptional loss of ₹4,458 Lakhs, including an impairment charge related to the BACC divestment.\n*   \u003Cb>Strategic Divestment:\u003C\u002Fb> Approved the sale of its entire stake in the non-core fertility business, BACC Health Care Private Limited, for a consideration of ~₹37.64 Crores. This is a related party transaction.\n*   \u003Cb>New CFO:\u003C\u002Fb> Appointed Mr. Sanjeev Kumar as Chief Financial Officer and Key Managerial Personnel, effective May 25, 2026.\n*   \u003Cb>Capital Raise:\u003C\u002Fb> Completed a rights issue raising over ₹42,000 Lakhs, with the proceeds currently unutilised.\n*   \u003Cb>Auditor's Opinion:\u003C\u002Fb> Received an unmodified (clean) audit report on the financial statements for FY26.",{"company_name":532,"filing_date":533,"filing_source":9,"headline":534,"id":535,"stock_code":519,"summary_text":536},"Tamilnadu PetroProducts Limited","2026-05-19T22:46:41.404000","A Tale of Two Results: Full-Year Profit Soars 73% While Q4 Revenue Craters","6a0c9b35890e096a6fc5f963","- **Full-Year FY26 Performance:** Net Profit surged \u003Cb>72.6%\u003C\u002Fb> to ₹88.76 Cr, despite a \u003Cb>19.4%\u003C\u002Fb> drop in annual revenue. Management credits this to strong cost controls.\n- **Q4 FY26 Collapse:** The fourth quarter saw a dramatic revenue drop of \u003Cb>72.6%\u003C\u002Fb> and a net profit fall of \u003Cb>76.6%\u003C\u002Fb> compared to the same quarter last year.\n- **Increased Dividend:** The Board has recommended a higher dividend of \u003Cb>₹1.50 per share (15%)\u003C\u002Fb> for FY26, up from 12% in the previous year.\n- **Major Red Flag:** The severe Q4 revenue drop is a significant concern. Management cites \"macroeconomic headwinds\" and \"sharp increase in raw material costs\" as the cause.",{"company_name":538,"filing_date":539,"filing_source":9,"headline":540,"id":541,"stock_code":542,"summary_text":543},"Positron Energy Limited","2026-05-19T22:46:41.392000","Earnings Call Audio Recording Now Available","6a0c9b1dabd16353d200197a","POSITRON","*   The company has released the audio recording for its Analyst\u002FInvestors' Earnings Call held on May 19, 2026.\n*   This filing is in compliance with SEBI's disclosure regulations (Regulation 30 & 46).\n*   The company explicitly states that no Unpublished Price Sensitive Information (UPSI) was shared during the call.\n*   The audio recording link is available on the company's website.",{"company_name":443,"filing_date":545,"filing_source":9,"headline":546,"id":547,"stock_code":447,"summary_text":548},"2026-05-19T22:41:40.059000","Declares 200% Special Interim Dividend!","6a0c99e9a157653c663a7abf","*   The Board has declared a **Special Interim Dividend** of **₹4 per share** for the financial year ending March 31, 2026.\n*   This represents a dividend of **200%** on the face value of ₹2 per share.\n*   The **Record Date** to determine shareholder eligibility for the dividend is set for **Monday, May 25, 2026**.",{"company_name":450,"filing_date":550,"filing_source":31,"headline":551,"id":552,"stock_code":454,"summary_text":553},"2026-05-19T22:36:40.695000","Acquires STEAG Energy Services (SESI) in a ₹180 Cr All-Cash Deal","6a0c98f258d87443453a64bc","*   Announced the acquisition of 100% of STEAG Energy Services (India) for ₹180 Cr in an all-cash deal. The move is expected to add ~20% to topline and 90-100 bps to EBITDA margins.\n*   Core operations (excluding the `foundit` investment) show healthy growth, with FY26 revenue up 11% and Adjusted PAT up 27% YoY.\n*   The consolidated entity reported a net loss of ₹23 Cr for the year, primarily driven by losses from the `foundit` business.\n*   The Security segment was a standout performer, with Q4 EBITDA growing 203% YoY, while the Telecom segment faced a temporary headwind.",{"company_name":314,"filing_date":555,"filing_source":9,"headline":556,"id":557,"stock_code":184,"summary_text":558},"2026-05-19T22:36:39.984000","Profit Declines, JMD Resigns Amidst Subsidiary Impairment","6a0c98fb890e096a6fc5f958","*   Consolidated revenue fell 15.85% and Profit After Tax dropped 20.44% YoY, driven by a sharp 17.36% decline in the core Agro chemicals segment.\n*   The company recognized a significant impairment loss of ₹1,100 million on its investment in the pharma subsidiary, PI Health Sciences Limited (PIHS).\n*   Joint Managing Director Mr. Rajnish Sarna has resigned, citing \"health recovery\". He will continue as a Non-Executive, Non-Independent Director.\n*   Despite 40% revenue growth, the Pharma segment remains loss-making with a pre-tax loss of ₹2,744 million for the year.\n*   The Board recommended a final dividend of ₹10 per share, bringing the total for FY26 to ₹15 per share.\n*   Auditors flagged recurring weaknesses in the accounting software's \"audit trail\" functionality and a failure to file quarterly bank returns on time.",{"company_name":484,"filing_date":560,"filing_source":9,"headline":561,"id":562,"stock_code":454,"summary_text":563},"2026-05-19T22:36:39.871000","Acquires Energy Firm, Core Business Soars in FY26","6a0c98e5abd16353d200196f","*   Announced the 100% acquisition of STEAG Energy Services (SESI) for ₹180 Cr. The deal is expected to add ~20% to revenue and significantly boost EBITDA margins.\n*   The core business (ex-foundit) delivered strong FY26 results, with revenue growing 11% to ₹3,304 Cr and EBITDA up 9% to ₹163 Cr.\n*   The Security segment was the standout performer in Q4, with EBITDA growing by a massive 203% year-over-year.\n*   The `foundit` investment continues to be a significant drag on profitability, reducing the consolidated FY26 Profit After Tax (PAT) from an adjusted ₹67 Cr to just ₹14 Cr.\n*   Adjusted EPS (excluding foundit) grew 27% YoY to ₹4.5, reflecting the strong underlying health of the core operations.",{"company_name":565,"filing_date":566,"filing_source":9,"headline":567,"id":568,"stock_code":569,"summary_text":570},"Ducol Organics And Colours Limited","2026-05-19T22:36:39.854000","Confirms No Deviation in IPO Fund Utilization for FY26","6a0c98d50c6b4fb98a929773","DUCOL","*   The company has declared **no deviation or variation** in the utilization of its IPO funds for the quarter and year ended March 31, 2026.\n*   A total of **₹31.43 crore (99.76%)** of the IPO proceeds have been utilized as of March 31, 2026, in line with the objects stated in the offer document.\n*   The unutilized balance of ₹7.62 lakh is parked in a Fixed Deposit with a bank.\n*   The filing is accompanied by a certificate from the statutory auditor, Choudhary Choudhary & Co., confirming the fund utilization status.",{"company_name":484,"filing_date":572,"filing_source":9,"headline":573,"id":574,"stock_code":454,"summary_text":575},"2026-05-19T22:36:39.797000","FY26 Results: Core Business Booms, Two Major Acquisitions to Add ~20% to Topline","6a0c98dfa157653c663a7ab7","*   For FY26 (excl. 'foundit'), the company reported strong growth with Revenue of ₹3,304 Cr and Adjusted PAT growth of 27% YoY.\n*   Security Services was a standout performer with 203% YoY EBITDA growth in Q4, while Facility & Food Services also showed robust 56% YoY EBITDA growth.\n*   The 'Investments - foundit' segment remains a significant drag, posting a negative EBITDA of ₹(43) Cr for FY26. Management is targeting an EBITDA break-even for this unit.\n*   Two material acquisitions are pending (STEAG India & LSG Sky Chefs), with the STEAG deal alone expected to add ~20% to the company's topline and expand overall EBITDA margins.",{"company_name":464,"filing_date":577,"filing_source":31,"headline":578,"id":579,"stock_code":447,"summary_text":580},"2026-05-19T22:32:00.767000","Posts 17% PAT Growth, Declares ₹9 Dividend & Enters Real Estate","6a0c97bb0c6b4fb98a92976d","*   **FY26 Financials:** Consolidated Profit After Tax (PAT) grew 17.1% YoY to ₹23,090 Lakhs. Revenue from Operations increased by 15.8% YoY.\n*   **Bumper Dividend:** A total dividend of ₹9 per share was announced for FY26 (₹4 Special Interim + ₹5 recommended Final).\n*   **Real Estate Diversification:** The Board approved a foray into real estate with a ₹45 Crore residential project in Thane, a significant shift from its core textile business.\n*   **Subsidiary Impairment:** Recognized an impairment loss of ₹337.29 Lakhs on its investment in the foreign subsidiary, Cadini SRL, indicating financial risk.",{"company_name":582,"filing_date":583,"filing_source":31,"headline":584,"id":585,"stock_code":586,"summary_text":587},"SGL Resources Ltd","2026-05-19T22:32:00.749000","Bags New Domestic Order Worth ₹4.35 Crore!","6a0c97af58d87443453a64b6","526544","• \u003Cb>Order Value:\u003C\u002Fb> ₹4.35 Crore\n• \u003Cb>Awarded by:\u003C\u002Fb> Heliocentrix Technology Private Limited\n• \u003Cb>Scope:\u003C\u002Fb> Supply of GIS-based field survey solutions, software, and maintenance.\n• \u003Cb>Timeline:\u003C\u002Fb> To be executed within 1 year.\n• \u003Cb>Note:\u003C\u002Fb> The order is not a related party transaction.",{"company_name":450,"filing_date":589,"filing_source":31,"headline":590,"id":591,"stock_code":454,"summary_text":592},"2026-05-19T22:32:00.742000","FY26 Results: Core Business Grows 11%, Major Acquisitions to Add 20%+ to Revenue","6a0c97bfbf8f716f13000575","*   Core business (excl. 'foundit') revenue grew 11% YoY to ₹3,304 Cr for FY26, with Adjusted PAT up 27% YoY.\n*   Two major acquisitions (STEAG India & LSG Sky Chefs) are set to close soon, expected to add ~20% to revenue and expand EBITDA margins by 90-100 bps.\n*   The 'foundit' investment remains a drag, posting an EBITDA loss of ₹43 Cr for the year. Management is now targeting an EBITDA break-even for this segment.\n*   Security Services was a standout performer, with Q4 EBITDA growing 203% YoY.",true,100,1,2541]